Use of adenylate cyclase or bacteria producing it as vaccines against bordetella

Abstract

The invention provides for the utilisation of a bacterial vaccining preparation elaborated from a given bacterium of the genus Bordetella or an adenyl cyclase in order to prepare an antigen for the protection of human beings or animals against infections and the toxic effects caused by a bacterium of the genus Bordetella but different from that of the vaccining preparation.

1 . Use of a bacterial vaccinating preparation developed from a given bacterium of the Bordetella genus for the preparation of a protective antigen for man and animals against the infections and the toxic effects caused by a bacterium of the Bordetella genus but different from that of the vaccinating preparation.  
     
     
         2 . Use of a vaccinating preparation developed from an adenylate cyclase of a given bacterium of the Bordetella genus for the preparation of a protective antigen for man or animals against the infections and the toxic effects caused by a bacterium of the Bordetella genus different from that from which the adenylate cyclase is derived, the said adenylate cyclase being such as that obtained by placing the supernatant of a bacterial culture of Bordetella in contact with a Affigel-calmodulin® gel.  
     
     
         3 . Use according to  claim 1  or  2 , characterized in that the bacteria of the Bordetella genus are selected from  B.pertussis, B.parapertussis , and  B.bronchiseptica.    
     
     
         4 . Use according to  claim 3 , characterized in that the vaccinating preparation is developed from  B.bronchiseptica  or from the adenylate cyclase of  B.bronchiseptica  and that it is used in order to prepare a protective antigen against the infections and the toxic effects caused by  B.pertussis  or  B.parapertussis , the said adenylate cyclase being such as that obtained by placing the supernatant of a bacterial culture of Bordetella in contact with a Affigel-calmodulin® gel.  
     
     
         5 . Use according to  claim 3 , characterized in that the vaccinating preparation is developed from  B.pertussis  or the adenylate cyclase of  B.pertussis  and that it is used in order to prepare a protective antigen against the infections and the toxic effects caused by  B.bronchiseptica  or  B.parapertussis , the said adenylate cyclase being such as that obtained by placing the supernatant of a bacterial culture of Bordetella in contact with a Affigel-calmodulin® gel.  
     
     
         6 . Use according to  claim 3 , characterized in that the vaccinating preparation is developed from B.parapertussis or the adenylate cyclase of  B.parapertussis  and that it is used in order to prepare a protective antigen against the infections and the toxic effects caused by  B.pertussis  or  B.bronchiseptica , the said adenylate cyclase being such as that obtained by placing the supernatant of a bacterial culture of Bordetella in contact with a Affigel-calmodulin® gel.  
     
     
         7 . Vaccines capable of inducing protection against the toxic effects and the infections caused by the Bordetella, characterized in that they are molecular vaccines containing at least the active part of the amino acid sequence represented in the figure, where appropriate combined or not, in the same inoculum, with FHA and/or PTx.  
     
     
         8 . Use according to any one of the  claims 1  to  6 , characterized in that the vaccinating preparations are combined or not, in the same inoculum, with FHA and/or PTx.